Healthspan becomes a clearer investment theme in preventive wellness

Genflow Biosciences Plc

Lifespan is the number of years a person lives. Healthspan is the number of years they remain healthy, active and independent. That distinction is becoming more relevant as consumers look for practical ways to support long-term wellbeing before problems become more difficult to manage.

Better long-term health is linked to everyday habits that can be repeated and measured. Regular exercise, good sleep, strength, movement and recovery all play a role. These are not complex ideas, but they are becoming more commercially important as consumers place greater value on prevention, consistency and personal health awareness.

This creates a useful backdrop for the wider wellness and health technology market. Products and services that help people understand daily behaviour may benefit from rising interest in healthy ageing. The opportunity is not limited to elite athletes or highly active consumers. It also applies to people who want to maintain independence, improve resilience and reduce lifestyle-related health risks over time.

Cardiovascular fitness is presented as a marker linked with stronger long-term health. Sleep consistency is also relevant, as recovery depends not only on duration but also on regular patterns. Strength training supports physical function as people age, while daily movement such as walking can contribute to overall wellbeing. Recovery is another important area because it helps connect short-term lifestyle choices with longer-term health goals.

Genflow Biosciences plc (LON:GENF, OTCQB:GENFF, FRA:WQ5) is a UK-based biotech firm with R&D facilities in Belgium focused on developing novel therapeutic approaches that potentially halt or slow the aging process in humans and dogs supporting longer, healthier lives

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Genflow reports biological age reductions in dog gene therapy study

Genflow Biosciences reports reductions in measured epigenetic age in dogs receiving SIRT6c gene therapy, selecting intravenous plasmid DNA as its lead veterinary delivery method while further follow-up continues.

Genflow Biosciences secures Japanese patent and expands animal health partnerships

Genflow Biosciences has secured Japanese patent allowance for its SIRT6 gene therapy, with all 16 claims approved, and signed additional confidentiality agreements with animal health companies. Its regional grant application is under review, with no impact on financial guidance expected.

Genflow Biosciences: SLAB-VET Results Put SIRT6 Partnering and Human Therapies in Focus (video)

Genflow Biosciences’ latest SLAB-VET-001 results are sharpening the commercial case for its SIRT6c platform. CEO Dr Eric Leire discusses the signals seen in naturally aged dogs, why pDNA is leading the veterinary programme, growing interest from animal health companies and how progress could feed into Genflow’s human sarcopenia strategy.

Genflow Biosciences examines the role of genes in ageing

Genflow Biosciences is investigating a SIRT6 gene variant associated with longevity as part of its research into therapies targeting biological ageing.

Genflow reports SIRT6 gene therapy results in aged dogs

Genflow reports reduced epigenetic age in dogs treated with its SIRT6c gene therapy, with pDNA selected as the lead delivery method for its veterinary programme.

Genflow completes SLAB trial as human and animal health programmes advance

Genflow Biosciences completed its SLAB canine healthspan and sarcopenia trial in H1 2026, with the company reporting safety and tolerability data for GF-1004. The group also advanced its glaucoma, MASH, Mitosir and Exofastrack programmes while ending the period with £632,553 in cash.

Search